CHAD Therapeutics Inc. will sell off its oxygen conserver business to Inovo Inc., a privately held manufacturer based in Florida in a deal worth $5.25 million. Chatsworth-based CHAD would not incur a loss on the sale of these assets based on the current selling price, a company representative said. Inovo assumes certain liabilities and obligations related to CHAD’s oxygen conserver business. CHAD will retain the assets related to its TOTALO2 system and in-home oxygen transfilling business as well as products in development for the sleep disorder market. The agreement is subject to certain closing conditions, including approval of CHAD’s shareholders.
